Joshua F. Zeidner, MD (IMAGE)

University of North Carolina Health Care

Joshua F. Zeidner, MD

Caption

“The promising findings from our phase 1 safety trial have directly led to the design and implementation of a randomized phase 3 study to determine whether the addition of revumenib to standard azacitidine and venetoclax improves overall survival in people with NPM1m or KMT2Ar AML,” said Joshua F. Zeidner, MD. “This regimen has the potential to be practice-changing for patients whose AML harbors the specific gene alterations we focused on.”

Credit

UNC Lineberger Comprehensive Cancer Center

Usage Restrictions

None

License

Licensed content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.